Recruiting

The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study

The Multi-OutcoMe EvaluatioN of radiation Therapy Using the Unity MR-Linac Study (MOMENTUM) is a multi-institutional, international registry facilitating evidenced based implementation of the Unity MR-Linac technology and further technical development of the MR-Linac system with the ultimate purpose to improve patients' survival, local, and regional tumor control and quality of life.

ClinicalTrials.gov IDNCT04075305

PhaseNot Applicable

Enrollment8000

SponsorUMC Utrecht

Age18 Years

SexALL

I'm interested View official listing

Conditions studied

Oncology, Breast Cancer, Prostate Cancer, Gynecologic Cancer, Brain Tumor, Brain Cancer, Gynecologic Tumor, Prostate Tumor, Prostate Neoplasm, Breast Tumor, Radiation Toxicity, Quality of Life, Rectal Cancer, Rectal Tumor, Rectal Neoplasms, Lung Cancer, Lung Tumor, Lung Neoplasm, Esophageal Cancer, Esophagus Cancer, Esophageal Tumor, Esophageal Neoplasm, Esophagus Tumor, Esophagus Neoplasm, Pancreatic Cancer, Pancreatic Tumor, Pancreatic Neoplasms, Head and Neck Cancer, Head and Neck Neoplasms, Head and Neck Tumor, Tumor, Neoplasms, Bladder Cancer, Bladder Neoplasm, Liver Cancer, Liver Neoplasms, Liver Metastases, Oligometastases

About this study

Interventions

Radiation: Radiation therapy — Radiation therapy on the CE marked and FDA approved MR-Linac

Primary outcomes

Progression-free Survival (3 months after MR-Linac treatment)
Progression-free Survival (6 months after MR-Linac treatment)
Progression-free Survival (24 months after MR-Linac treatment)
Survival (3 months after MR-Linac treatment)
Survival (6 months after MR-Linac treatment)
Survival (24 months after MR-Linac treatment)
Disease-free Survival (3 months after MR-Linac treatment)
Disease-free Survival (6 months after MR-Linac treatment)

Eligibility information

Inclusion Criteria: * Patient is to undergo or has completed imaging or treatment procedures on an MR-Linac; * Patient provides written, informed consent; * Patient is 18 years old or older. Exclusion Criteria: * MRI exclusion criteria, including * MRI contraindications as per usual clinical care, such as (possible) pregnancy; claustrophobia and metal or electronic implants not compatible with MRI.

Study locations

Allegheny Health Network, Pittsburgh, Pennsylvania 15212 United States
Md Anderson Cancer Center, Houston, Texas 77030 United States
Medical College of Wisconsin, Milwaukee, Wisconsin 53226 United States
Austin Health - Olivia Newton-John Cancer Wellness and Research Centre, Melbourne, Australia
Insitut Jules Bordet, Brussels, Belgium
Sunnybrook Health Sciences Centre/Odette Cancer Centre, Toronto, Ontario Canada
University Health Network - Princess Margaret Cancer Center, Toronto, Canada
Odense Universitetshospital, Odense, Funen 5000 Denmark
Universitätsklinikum Tübingen, Tübingen, Germany
Università degli Studi di Brescia, Brescia, Italy

Showing 10 of 18 reported sites. See the official listing for all locations.

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.